Skip to main content

Table 1 Demographics, characteristics, and interventions of eyes with visual impairment from center-involved diabetic macular edema stratified by visual acuity response at one year following treatments

From: Factors associated with 1-year visual response following intravitreal bevacizumab treatment for diabetic macular edema: a retrospective single center study

Characteristics Overall (N = 226 Eyes) Gain ≥ 10 Letters at 1 Year (N = 110 Eyes) Gain < 10 Letters at 1 Year (N = 116 Eyes) P Value*
Demographics
 Age ≥ 60 years, n (%) 78 (34.5) 30 (27.3) 48 (41.4) 0.041
 Male, n (%) 122 (54) 66 (60) 56 (48.3) 0.112
 Severe NPDR to PDR stage, n (%) 158 (69.9) 75 (68.2) 83 (71.6) 0.638
 Previous macular laser photocoagulation, n (%) 42 (18.6) 13 (11.8) 29 (25) 0.019
 Previous PRP, n (%) 63 (27.9) 28 (25.5) 35 (30.2) 0.528
 Phakia, n (%) 202 (89.4) 102 (92.7) 100 (86.2) 0.115
Ocular characteristics at baseline
 Mean (SD) VA, letter 51.8 (19.1) 46 (21) 57.3 (15.2)  < 0.001
 VA ≥ 69 letters, n (%) 63 (27.9) 23 (20.9) 40 (34.5) 0.025
 Mean CSFT (SD), µm 496.2 (145.2) 513.9 (164.5) 479.4 (122.6) 0.159
 CSFT ≥ 400 µm 163 (72.1) 80 (72.3) 83 (81.6) 0.983
 ERM, n (%) 28 (12.4) 7 (6.4) 21 (18.1) 0.012
 DRIL, n (%) 65 (28.8) 24 (21.8) 41 (35.3) 0.026
 HF, n (%) 99 (43.8) 52 (47.3) 47 (40.5) 0.257
 IRC ≥ 600 µm, n (%) 23 (10.2) 9 (8.2) 14 (12.1) 0.399
 Disruption of ELM, n (%) 61 (26.9) 30 (27.3) 31 (26.7) 0.858
 Disruption of EZ, n (%) 56 (24.8) 18 (16.4) 38 (32.8) 0.003
 SRF, n (%) 113 (50) 59 (53.6) 54 (46.6) 0.316
 Foveal exudate, n (%) 15 (6.6) 6 (5.5) 9 (7.8) 0.507
Ocular characteristics at week 12
 Mean (SD) VA, letter 61.7 (17.8) 63.6 (17.8) 59.9 (17.7) 0.172
 VA gain < 5 letters, n (%) 80 (35.4) 13 (11.8) 67 (57.8)  < 0.001
 CSFT reduction < 10%, n (%) 78 (34.5) 27 (24.6) 51 (44.0) 0.004
 DRIL, n (%) 42 (18.6) 13 (11.8) 29 (25) 0.012
 HF, n (%) 63 (27.9) 31 (28.2) 32 (27.6) 0.812
 IRC ≥ 600 µm, n (%) 15 (6.6) 4 (3.6) 11 (9.5) 0.046
 Disruption of ELM, n (%) 43 (19) 12 (10.9) 31 (26.7) 0.002
 Disruption of EZ, n (%) 44 (19.5) 12 (10.9) 32 (27.6) 0.002
 SRF, n (%) 41 (18.1) 24 (21.8) 17 (14.7) 0.256
 Foveal exudate, n (%) 17 (7.5) 6 (5.5) 11 (9.5) 0.428
During 12 months
 Mean (SD) number of injections 7.3 (3.2) 6.9 (3.2) 7.5 (3.2) 0.183
 Receiving additional macular laser photocoagulation, n (%) 127 (56.2) 59 (53.6) 68 (58.6) 0.494
  1. VA visual acuity,SD standard deviation, NPDR  non-proliferative diabetic retinopathy,PDR proliferative diabetic retinopathy, PRP  panretinal photocoagulation, CSFT central subfield thickness, ERM  epiretinal membrane, DRIL disorganization of retinal inner layer, HF hyperreflective foci, IRC intraretinal cyst, ELM external limiting membrane, EZ ellipsoid zone, SRF subretinal fluid
  2. *generalized estimating equation (GEE)
Back to article page

International Journal of Retina and Vitreous

ISSN: 2056-9920

Contact us

\